Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

SK Biopharmaceuticals Co., Ltd. (326030) Stock Price & Analysis

326030 Stock Chart & Stats

$77,700.00-$100.00(-0.13%)
At close: 3:30 PM GMT+9
$70,000$80,000$90,0003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$76,000.00 - $79,000.00
52-Week Range
$67,800.00 - $144,100.00
Previous Close
$77,800.00
Volume
N/A
Average Volume (3M)
97.70K
Market Cap
KRW 6.08T
Enterprise Value
KRW 6.45T
Total Cash (Recent Filing)
KRW 381.87B
Total Debt (Recent Filing)
KRW 48.83B
Price to Earnings (P/E)
15.7
Beta
0.25
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
776
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Profitability And Growth

The company has moved from prior losses to strong TTM profitability while maintaining positive revenue growth. High gross and operating margins indicate meaningful earnings power, giving SK Biopharmaceuticals greater capacity to fund research, commercialization, and pipeline expansion internally.

Conservative Balance Sheet

Very low leverage materially reduces financial risk and preserves flexibility for clinical development, commercial investment, and strategic opportunities. The expansion of assets and equity alongside improved returns provides a stronger foundation than the company had during earlier loss-making periods.

Positive Cash Generation

Free cash flow closely tracking net income suggests that recent reported profits are supported by cash rather than being purely accounting-driven. If maintained, this conversion can help finance pipeline development and commercial growth while reducing reliance on external capital.

Bears Say

Historically Volatile Earnings

The sharp transition from losses to strong profitability demonstrates that earnings have not yet been stable across the cycle. Such volatility makes future performance harder to forecast and raises the risk that current margins may not fully represent normalized long-term operating results.

Cash Conversion Durability Remains Unproven

Although current free cash flow is positive, operating cash flow has not consistently matched accounting earnings and was negative in earlier years. This history leaves uncertainty about whether cash generation can remain durable through a full development and commercialization cycle.

Early-stage Pipeline Investment Risk

The Parkinson’s licensing deal broadens the neurological pipeline, but the candidate remains early stage and its potential value depends on clinical and regulatory success. The sizeable investment therefore carries execution risk before it can contribute meaningful commercial revenue.

SK Biopharmaceuticals Co., Ltd. News

326030 FAQ

What was SK Biopharmaceuticals Co., Ltd.’s price range in the past 12 months?
SK Biopharmaceuticals Co., Ltd. lowest stock price was $67800.00 and its highest was $144100.00 in the past 12 months.
What is SK Biopharmaceuticals Co., Ltd.’s market cap?
SK Biopharmaceuticals Co., Ltd.’s market cap is ₩6.08T.
When is SK Biopharmaceuticals Co., Ltd.’s upcoming earnings report date?
SK Biopharmaceuticals Co., Ltd.’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 3 days.
How were SK Biopharmaceuticals Co., Ltd.’s earnings last quarter?
SK Biopharmaceuticals Co., Ltd. released its earnings results on Aug 05, 2026. The company reported $1,086.15 earnings per share for the quarter, beating the consensus estimate of $581.55 by $504.6.
Is SK Biopharmaceuticals Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does SK Biopharmaceuticals Co., Ltd. pay dividends?
SK Biopharmaceuticals Co., Ltd. does not currently pay dividends.
What is SK Biopharmaceuticals Co., Ltd.’s EPS estimate?
SK Biopharmaceuticals Co., Ltd.’s EPS estimate is 776.00.
How many shares outstanding does SK Biopharmaceuticals Co., Ltd. have?
SK Biopharmaceuticals Co., Ltd. has 78,313,250 shares outstanding.
What happened to SK Biopharmaceuticals Co., Ltd.’s price movement after its last earnings report?
SK Biopharmaceuticals Co., Ltd. reported an EPS of $1,086.15 in its last earnings report, beating expectations of $581.55. Following the earnings report the stock price went up 2.757%.
Which hedge fund is a major shareholder of SK Biopharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in KR:326030
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology